![A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas | British Journal of Cancer A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-019-0503-9/MediaObjects/41416_2019_503_Fig1_HTML.png)
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas | British Journal of Cancer
![Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial - ScienceDirect Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S155608642300730X-gr3.jpg)
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial - ScienceDirect
![PDF) Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy PDF) Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy](https://www.researchgate.net/publication/326825158/figure/tbl2/AS:11431281145363792@1681408726342/Alectinib-safety-in-selected-and-discussed-clinical-trials_Q320.jpg)